Cancer patients are often treated with multiple rounds of a therapy until disease progression occurs and accordingly, we next investigated if a more profound resistance to SAR405838 can be developed when the xenograft tumors established from the 7.6 SJSA-1 subline containing a wild-type p53 are treated with SAR405838 in mice. The gene discussed is TP53; the disease is cancer.